Special Issue

Epidemiology and Pathogenomics of the *Corynebacterium* Genus

Message from the Guest Editor

The genus *Corynebacterium* is highly significant, as it includes a diverse range of bacterial species that play crucial roles in both human health and industrial applications. In this Special Issue, we will focus specifically on human and animal health. The most well-known member of this genus in human health is *Corynebacterium* diphtheriae, the causative agent of diphtheria. While *C. diphtheriae* is the primary concern, other *Corynebacterium* species are increasingly recognized as opportunistic pathogens. These species can cause various infections, including Bacteremia and sepsis (*C. jeikeium*, *C. urealyticum*);Urinary tract infections (*C. urealyticum*); Skin and soft tissue infections (*C. striatum*, *C. jeikeium*); Respiratory infections (*C. striatum*, *C. pseudodiphtheriticum*); Endocarditis. In this Special Issue, we will bring together researchers working in omics to monitor the evolution of these bacteria. Our goal is to deepen our understanding of the mechanisms involved, which will aid in the development of new vaccines, diagnostics, and treatments.

Guest Editor

Prof. Dr. Vasco Azevedo

1. Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil
2. Department of Animal Science, Federal University of Bahia, Av. Adhemar de Barros, 500, Salvador 40170-110, Brazil

Deadline for manuscript submissions

31 August 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/246271

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI